First-generation mTOR inhibitors (rapalogs) that target mTOR complex 1 (mTORC1, e.g., temsirolimus and ridaforolimus), have demonstrated preliminary antitumor activity in small patient populations with recurrent endometrial cancer. Here, MTOR is linked to endometrial cancer.